The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
Open accessThe DOI matches its Crossref record; 175 of the 177 references it cites were found in a registry or an index.
Abstract
Unconjugated anti-cancer IgG1 monoclonal antibodies (mAbs) activate antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells and antibody-dependent cellular phagocytosis (ADCP) by macrophages, and these activities are thought to be important mechanisms of action for many of these mAbs in vivo. Several mAbs also activate the classical complement pathway and promote complement-dependent cytotoxicity (CDC), although with very different levels of efficacy, depending on the mAb, the target antigen, and the tumor type. Recent studies have unraveled the various structural factors that define why some IgG1 mAbs are strong mediators of CDC, whereas others are not. The role of complement activation and membrane inhibitors expressed by tumor cells, most notably CD55 and CD59, has also been quite extensively studied, but how much these affect the resistance of tumors in vivo to IgG1 therapeutic mAbs still remains incompletely understood. Recent studies have demonstrated that complement activation has multiple effects beyond target cell lysis, affecting both innate and adaptive immunity mediated by soluble complement fragments, such as C3a and C5a, and by stimulating complement receptors expressed by immune cells, including NK cells, neutrophils, macrophages, T cells, and dendritic cells. Complement activation can enhance ADCC and ADCP and may contribute to the vaccine effect of mAbs. These different aspects of complement are also briefly reviewed in the specific context of FDA-approved therapeutic anti-cancer IgG1 mAbs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Epcoritamab is a subcutaneously administered bispecific antibody approved in numerous countries as monotherapy for follicular lymphoma after two or more lines of therapy.”
From Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Adverse events were manageable and consistent with the established safety profiles of the individual components of the triplet, 5,13,18 with no new safety findings.”
From Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. (2026) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Jiang, H., Acharya, C., An, G., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., et al. (2016) · Leukemia · doi:10.1038/leu.2015.240 · Cited by 219
RetractedInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Complement System Part I – Molecular Mechanisms of Activation and Regulation
Merle, N. S., Church, S. E., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00262 · Cited by 1,620
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., de la Serna, J., Dilhuydy, M.-S., Illmer, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313984 · Cited by 1,518 · cited 1×
“In some cases, the studies that have compared obinutuzumab with rituximab have shown a significant advantage of the former, particularly in CLL in combination with chlorambucil [166,167].”
ResultComplement System Part II: Role in Immunity
Merle, N. S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00257 · Cited by 1,051 · cited 1×
“On this basis, it should be clear that C9 polymerization generally correlates with effective cell lysis [30,32,33].”
Backgroundde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981 · cited 1×
“In contrast, obinutuzumab is only a weak complement activator [11,50] (a type II antibody).”
BackgroundKrejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 954 · cited 2×
“Daratumumab and isatuximab have also been reported to deplete CD38+ immune regulatory cells, such as Treg, Breg, and myeloid derived suppressor cells (MDSCs) in vitro and in vivo [132,133].”
BackgroundProperties of mouse and human IgG receptors and their contribution to disease models
Bruhns, P. (2012) · Blood · doi:10.1182/blood-2012-01-380121 · Cited by 847 · cited 1×
“The major caveat of studies in mice is that both complement and FcγRs differ considerably between mice and humans, and some complement inhibitory proteins are species specific, so that the relative roles of CDC, ADCC, and ADCP in mice may not fully recapitulate the human situation [74,136].”
BackgroundComplement Is Activated by IgG Hexamers Assembled at the Cell Surface
Diebolder, C. A., Beurskens, F. J., de Jong, R. N., Koning, R. I., Strumane, K., Lindorfer, M. A., Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A. J. R., et al. (2014) · Science · doi:10.1126/science.1248943 · Cited by 796 · cited 2×
“Fc mutations that favor hexamerization of antibodies targeting EGFR, CD38, or CD37 can render them strong effectors through CDC [24,25,44,45,57,58] and are being developed for clinical use [59,60].”
BackgroundSelf-citationNext generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754 · cited 1×
“Some have antigen neutralizing functions, as expected, since they target important growth factor receptors such as human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), chemokine receptor 4 (CCR4), or enzymes (CD38) expressed on the plasma membranes of the cancer cells [4,8].”
BackgroundBuilding better monoclonal antibody-based therapeutics
Weiner, G. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3930 · Cited by 712
Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., & Tedder, T. F. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040119 · Cited by 642
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.-M., Bernasconi, S., Tedesco, F., Rambaldi, A., & Introna, M. (2000) · Blood · doi:10.1182/blood.v95.12.3900 · Cited by 604 · cited 2×
“CD55 and CD59 act synergistically to protect cells so that blocking both molecules simultaneously generally leads to the best enhancement of CDC [63,65,75].”
BackgroundSelf-citationComplement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 576
Self-citationImportance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy
Gong, Q., Ou, Q., Ye, S., Lee, W. P., Cornelius, J., Diehl, L., Lin, W. Y., Hu, Z., Lu, Y., Chen, Y., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.817 · Cited by 543
The role of membrane receptors for C3b and C3d in phagocytosis.
Ehlenberger, A. G., & Nussenzweig, V (1977) · The Journal of experimental medicine · doi:10.1084/jem.145.2.357 · Cited by 534
From the bench to the bedside: ways to improve rituximab efficacy
Cartron, G., Watier, H., Golay, J., & Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2004-03-1110 · Cited by 523
Self-citationOverdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521 · cited 11×
“Interestingly, in MM patients who progressed after daratumumab treatment, their malignant plasma cells had elevated levels of CD55 and CD59, but not of CD46, suggesting that resistance to daratumumab in vivo may be related at least in part to resistance to CDC [80].”
BackgroundInfluentialMechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515 · cited 1×
“Thus, in vivo, exhaustion of effector mechanisms, including complement and effector cells such as NK and macrophages, as well as loss of target antigen by trogocytosis or internalization, can limit the efficacy of anti-tumor mAbs [18,134,139,152,155,156].”
BackgroundSelf-citationKarsten, C. M., Pandey, M. K., Figge, J., Kilchenstein, R., Taylor, P. R., Rosas, M., McDonald, J. U., Orr, S. J., Berger, M., Petzold, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2862 · Cited by 479 · cited 1×
“C3a and C5a also increase the permeability of small blood vessels through this inflammatory reaction and facilitate immune cell recruitment to sites of complement activation [35].”
BackgroundMollnes, T. E., Brekke, O., Fung, M. S. C., Fure, H., Christiansen, D., Bergseth, G., Videm, V., Lappegård, K. T., Köhl, J., & Lambris, J. D. (2002) · PubMed · doi:10.1182/blood.v100.5.1869.h81702001869_1869_1877 · Cited by 455 · cited 2×
“The best compounds to block coagulation in these assays are hirudin and its derivatives, since these molecules block thrombin activation but do not affect the complement cascade, unlike most other anticoagulants [50,64,119].”
BackgroundGolay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., & Introna, M. (2001) · Blood · doi:10.1182/blood.v98.12.3383 · Cited by 428 · cited 4×
“CD55 and CD59 act synergistically to protect cells so that blocking both molecules simultaneously generally leads to the best enhancement of CDC [63,65,75].”
BackgroundSelf-citationComplement in cancer: untangling an intricate relationship
Reis, E. S., Mastellos, D. C., Ricklin, D., Mantovani, A., & Lambris, J. D. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.97 · Cited by 425
Meri, S., & Pangburn, M. K. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.10.3982 · Cited by 412 · cited 1×
“Membrane protein sialylation also inhibits complement at least in part by promoting binding of FH [92] and this has been suggested as an additional mechanism of resistance of CLL cells to anti-CD20 mediated lysis.”
BackgroundNijhof, I. S., Casneuf, T., van Velzen, J., van Kessel, B., Axel, A. E., Syed, K., Groen, R. W. J., van Duin, M., Sonneveld, P., Minnema, M. C., et al. (2016) · Blood · doi:10.1182/blood-2016-03-703439 · Cited by 393 · cited 1×
“Interestingly, in MM patients who progressed after daratumumab treatment, their malignant plasma cells had elevated levels of CD55 and CD59, but not of CD46, suggesting that resistance to daratumumab in vivo may be related at least in part to resistance to CDC [80].”
BackgroundComplement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Cragg, M. S., Morgan, S. M., Chan, H. T. C., Morgan, B. P., Filatov, A. V., Johnson, P. W. M., French, R. R., & Glennie, M. J. (2003) · Blood · doi:10.1182/blood-2002-06-1761 · Cited by 390 · cited 2×
“In fact, the capacity of different anti-CD20 mAbs to translocate CD20 to lipid rafts correlates with their efficiency at inducing CDC [47,51].”
BackgroundPast, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
Pierpont, T. M., Limper, C. B., & Richards, K. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00163 · Cited by 374
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
Manches, O., Lui, G., Chaperot, L., Gressin, R., Molens, J.-P., Jacob, M.-C., Sotto, J.-J., Leroux, D., Bensa, J.-C., & Plumas, J. (2003) · Blood · doi:10.1182/blood-2002-02-0469 · Cited by 372 · cited 1×
“, follicular lymphoma cells) showed overall a better clinical response to rituximab therapy than in neoplasias in which the B cells (CLL cells) were only weakly killed by rituximab-mediated CDC [144].”
ResultKennedy, A. D., Beum, P. V., Solga, M. D., DiLillo, D. J., Lindorfer, M. A., Hess, C. E., Densmore, J. J., Williams, M. E., & Taylor, R. P. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.3280 · Cited by 359 · cited 3×
“Rapid complement activation with deposition of C3b and iC3b on the CLL cell membrane has been demonstrated very soon after rituximab and ofatumumab infusion [138,139].”
BackgroundSelf-citationCD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
van de Donk, N. W. C. J., & Usmani, S. Z. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02134 · Cited by 354
The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases
Hogan, K. A., Chini, C. C. S., & Chini, E. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01187 · Cited by 337 · cited 1×
“Finally anti-CD38 mAbs inhibit the CD38 ectoenzyme activity [135], thus diminishing immunosuppressive adenosine production.”
BackgroundBeers, S. A., French, R. R., Chan, H. T. C., Lim, S. H., Jarrett, T. C., Vidal, R. M., Wijayaweera, S. S., Dixon, S. V., Kim, H., Cox, K. L., et al. (2010) · Blood · doi:10.1182/blood-2010-01-263533 · Cited by 335
Complement activation plays a key role in the side‐effects of rituximab treatment
Van Der Kolk, L. E., Grillo‐López, A. J., Baars, J. W., Hack, C. E., & Van Oers, M. H. J. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03166.x · Cited by 327
Ferris, R. L., Jaffee, E. M., & Ferrone, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6360 · Cited by 320
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy
Gül, N., Babes, L., Siegmund, K., Korthouwer, R., Bögels, M., Braster, R., Vidarsson, G., ten Hagen, T. L. M., Kubes, P., & van Egmond, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66776 · Cited by 275
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
DiLillo, D. J., & Ravetch, J. V. (2015) · Cell · doi:10.1016/j.cell.2015.04.016 · Cited by 266 · cited 8×
“These reactions may eliminate the tumor cells through either FcγRs or complement receptors or both.”
BackgroundInfluentialPawluczkowycz, A. W., Beurskens, F. J., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G. J., Parren, P. W. H. I., & Taylor, R. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900632 · Cited by 262 · cited 1×
“For example, different anti-CD20 antibodies vary in their capacity to activate complement, with ofatumumab being the most effective, followed by rituximab [48,49] (both so-called type I anti-CD20 antibodies).”
BackgroundSelf-citationHarjunpää, Junnikkala, & Meri (2000) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2000.00745.x · Cited by 256 · cited 1×
“CD55 and CD59 act synergistically to protect cells so that blocking both molecules simultaneously generally leads to the best enhancement of CDC [63,65,75].”
Backgroundvan Meerten, T., van Rijn, R. S., Hol, S., Hagenbeek, A., & Ebeling, S. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0066 · Cited by 250
Beum, P. V., Kennedy, A. D., Williams, M. E., Lindorfer, M. A., & Taylor, R. P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2600 · Cited by 239
Self-citationGoede, V, Fischer, K., Engelke, A., Schlag, R., Lepretre, S., Montero, L. F. C., Montillo, M., Fegan, C., Asikanius, E., Humphrey, K., et al. (2015) · Leukemia · doi:10.1038/leu.2015.14 · Cited by 237 · cited 1×
“In some cases, the studies that have compared obinutuzumab with rituximab have shown a significant advantage of the former, particularly in CLL in combination with chlorambucil [166,167].”
Resultvan Imhoff, G. W., McMillan, A., Matasar, M. J., Radford, J., Ardeshna, K. M., Kuliczkowski, K., Kim, W., Hong, X., Goerloev, J. S., Davies, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.0198 · Cited by 235 · cited 1×
“There have also been few direct comparisons between ofatumumab and rituximab in the clinic [168].”
BackgroundNiederfellner, G., Lammens, A., Mundigl, O., Georges, G. J., Schaefer, W., Schwaiger, M., Franke, A., Wiechmann, K., Jenewein, S., Slootstra, J. W., et al. (2011) · Blood · doi:10.1182/blood-2010-09-305847 · Cited by 230 · cited 1×
“These studies nicely show how the specific epitope recognition of different mAbs can lead to different binding orientations, inter-molecular interactions, and structural constrictions that, in turn, lead to quite different capacities to activate complement, even if the mAbs are directed against the same antigen (CD20)…”
BackgroundThe Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Moreno, L., Perez, C., Zabaleta, A., Manrique, I., Alignani, D., Ajona, D., Blanco, L., Lasa, M., Maiso, P., Rodriguez, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1597 · Cited by 221 · cited 1×
“This means that an antibody with a greater CDC or ADCC potential in vitro may in any case be limited in vivo by these mechanisms [2,141,172].”
Backgroundde Jong, R. N., Beurskens, F. J., Verploegen, S., Strumane, K., van Kampen, M. D., Voorhorst, M., Horstman, W., Engelberts, P. J., Oostindie, S. C., Wang, G., et al. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002344 · Cited by 219
Minard-Colin, V., Xiu, Y., Poe, J. C., Horikawa, M., Magro, C. M., Hamaguchi, Y., Haas, K. M., & Tedder, T. F. (2008) · Blood · doi:10.1182/blood-2008-01-135160 · Cited by 218 · cited 1×
“However, other studies did not confirm this finding in different models [108].”
ResultWeng, W.-K., & Levy, R. (2001) · Blood · doi:10.1182/blood.v98.5.1352 · Cited by 218 · cited 1×
“Although some correlations have been found in cases of lymphoma patients treated with rituximab and chemotherapy [160,161], this has not been confirmed in other studies [162], even with rituximab used as monotherapy [163].”
ResultHamaguchi, Y., Uchida, J., Cain, D. W., Venturi, G. M., Poe, J. C., Haas, K. M., & Tedder, T. F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.4389 · Cited by 212
Schreiber, A. D., & Frank, M. M. (1972) · Journal of Clinical Investigation · doi:10.1172/jci106846 · Cited by 206 · cited 1×
“The opsonized cells can then be effectively removed from the circulation by fixed tissue macrophages that have receptors for cell-bound IgG and C3 fragments, as first demonstrated for other substrates almost 50 years ago [37,40,41].”
BackgroundDistinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
García-Foncillas, J., Sunakawa, Y., Aderka, D., Wainberg, Z., Ronga, P., Witzler, P., & Stintzing, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00849 · Cited by 201 · cited 1×
“Similar cross-talk has been shown for other antibodies such as cetuximab [9] and a complement optimized anti-EGFR mAb was found to induce enhanced ADCC by PMNs [124].”
BackgroundA tale of two antibodies: obinutuzumab versus rituximab
Freeman, C. L., & Sehn, L. H. (2018) · British Journal of Haematology · doi:10.1111/bjh.15232 · Cited by 201
Bologna, L., Gotti, E., Manganini, M., Rambaldi, A., Intermesoli, T., Introna, M., & Golay, J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000303 · Cited by 200 · cited 4×
“With such assays, it was possible to show that the most effective short-term depletion of neoplastic B cells in whole blood by rituximab and ofatumumab, but not obinutuzumab, requires complement and can be blocked by anti-C5 eculizumab [50,64].”
BackgroundSelf-citationLong-lasting antitumor protection by anti-CD20 antibody through cellular immune response
Abès, R., Gélizé, E., Fridman, W. H., & Teillaud, J.-L. (2010) · Blood · doi:10.1182/blood-2009-10-248609 · Cited by 198 · cited 7×
“Furthermore the expression of complement receptors on different immune cell types including DCs is not identical between mice and men, making the study of the relevance of a possible vaccine effect via these molecules even more difficult [130].”
BackgroundInfluentialThe mechanism of anti-CD20–mediated B cell depletion revealed by intravital imaging
Montalvao, F., Garcia, Z., Celli, S., Breart, B., Deguine, J., Van Rooijen, N., & Bousso, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70972 · Cited by 192
Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab
Rougé, L., Chiang, N., Steffek, M., Kugel, C., Croll, T. I., Tam, C., Estevez, A., Arthur, C. P., Koth, C. M., Ciferri, C., et al. (2020) · Science · doi:10.1126/science.aaz9356 · Cited by 190 · cited 2×
“Furthermore the orientation of binding of the different mAbs to CD20 are distinct so that that rituximab and ofatumumab binding rapidly leads to CD20 concatenation and hexamerization of the mAbs on the cell surface, appropriate for C1q binding [52,53].”
BackgroundTherapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
Marshall, M. J. E., Stopforth, R. J., & Cragg, M. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01245 · Cited by 183
Beers, S. A., Chan, C. H. T., James, S., French, R. R., Attfield, K. E., Brennan, C. M., Ahuja, A., Shlomchik, M. J., Cragg, M. S., & Glennie, M. J. (2008) · Blood · doi:10.1182/blood-2008-04-149161 · Cited by 180
Geller, A., & Yan, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01074 · Cited by 173 · cited 2×
“Cancer cells are known to express, and sometimes overexpress, the membrane complement inhibitor proteins CD46, CD55, and CD59 [33].”
BackgroundTaylor, R. P., & Lindorfer, M. A. (2014) · Blood · doi:10.1182/blood-2014-10-569244 · Cited by 163
Self-citationWilliams, M. E., Densmore, J. J., Pawluczkowycz, A. W., Beum, P. V., Kennedy, A. D., Lindorfer, M. A., Hamil, S., Eggleton, J. C., & Taylor, R. P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.7435 · Cited by 160 · cited 2×
“Trogocytosis has been shown to occur both in vitro and in vivo in CLL patients and is likely to be another mechanism of resistance to complement and cell-mediated cytotoxicity [85].”
BackgroundSelf-citationWang, G., de Jong, R. N., van den Bremer, E. T. J., Beurskens, F. J., Labrijn, A. F., Ugurlar, D., Gros, P., Schuurman, J., Parren, P. W. H. I., & Heck, A. J. R. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.05.016 · Cited by 160 · cited 2×
“Fc mutations that favor hexamerization of antibodies targeting EGFR, CD38, or CD37 can render them strong effectors through CDC [24,25,44,45,57,58] and are being developed for clinical use [59,60].”
BackgroundRacila, E. V., Link, B. K., Weng, W., Witzig, T. E., Ansell, S. M., Maurer, M. J., Huang, J., Dahle, C. E., Halwani, A. S., Levy, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0745 · Cited by 159
Balasa, B., Yun, R., Belmar, N. A., Fox, M., Chao, D. T., Robbins, M. D., Starling, G. C., & Rice, A. G. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1610-3 · Cited by 157 · cited 1×
“Also, the direct effects of the mAbs can, in some cases, synergize with immune-mediated mechanisms, as is the case for NK activation by anti-SLAMF7 mAb elotuzumab [174] or the T-cell-activating effect of anti-CD38 mAbs [100].”
BackgroundAtkinson, J. P., & Frank, M. M. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107769 · Cited by 157 · cited 1×
“The opsonized cells can then be effectively removed from the circulation by fixed tissue macrophages that have receptors for cell-bound IgG and C3 fragments, as first demonstrated for other substrates almost 50 years ago [37,40,41].”
BackgroundImmunotherapeutic mechanisms of anti-CD20 monoclonal antibodies
Taylor, R. P., & Lindorfer, M. A. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.011 · Cited by 154 · cited 1×
“Rituximab efficiently activates CDC, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP) in vitro, and these different mechanisms must all contribute to its efficacy [4,7].”
BackgroundSelf-citationWang, S., Veeramani, S., Racila, E. V., Cagley, J. R., Fritzinger, D. C., Vogel, C.-W., John, W. S., & Weiner, G. J. (2009) · Blood · doi:10.1182/blood-2009-01-200469 · Cited by 151
Binding mechanisms of therapeutic antibodies to human CD20
Kumar, A., Planchais, C., Fronzes, R., Mouquet, H., & Reyes, N. (2020) · Science · doi:10.1126/science.abb8008 · Cited by 151 · cited 1×
“Furthermore the orientation of binding of the different mAbs to CD20 are distinct so that that rituximab and ofatumumab binding rapidly leads to CD20 concatenation and hexamerization of the mAbs on the cell surface, appropriate for C1q binding [52,53].”
BackgroundMacor, P., Tripodo, C., Zorzet, S., Piovan, E., Bossi, F., Marzari, R., Amadori, A., & Tedesco, F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1811 · Cited by 150 · cited 1×
“Inhibiting CD55 and CD59 has also been shown to enhance the activity of rituximab in mouse xenograft models [83,84].”
BackgroundRoit, F. D., Engelberts, P. J., Taylor, R. P., Breij, E. C. W., Gritti, G., Rambaldi, A., Introna, M., Parren, P. W. H. I., Beurskens, F. J., & Golay, J. (2015) · Haematologica · doi:10.3324/haematol.2014.107011 · Cited by 149 · cited 1×
“Indeed, chemotherapy may negatively affect the cell-mediated mechanisms of therapeutic mAbs, but could also potentially affect complement mediated mechanisms, if modulation of target antigen or of complement factors is induced by drug treatment [176,177].”
BackgroundSelf-citationLee, C.-H., Romain, G., Yan, W., Watanabe, M., Charab, W., Todorova, B., Lee, J., Triplett, K., Donkor, M., Lungu, O. I., et al. (2017) · Nature Immunology · doi:10.1038/ni.3770 · Cited by 145 · cited 1×
“In support of this concept are studies of mutant anti-CD20 antibodies able to activate complement but unable to bind to FcγRs, which indicate that CDCC by NK cells and CDCP by macrophages does play a role in vitro and in vivo in a murine immunocompetent model [120].”
BackgroundSelf-citationKennedy, A. D., Solga, M. D., Schuman, T. A., Chi, A. W., Lindorfer, M. A., Sutherland, W. M., Foley, P. L., & Taylor, R. P. (2003) · Blood · doi:10.1182/blood-2002-03-0876 · Cited by 141 · cited 1×
“It is clear that manipulation of the complement cascade, through the design of anti-tumor mAbs with increased ability to activate complement [44,59,96], or with mAbs that hyperactivate the complement cascade [97] or block soluble or membrane bound inhibitors [63,84,91], may all be feasible strategies to enhance the CD…”
BackgroundSelf-citationBeum, P. V., Peek, E. M., Lindorfer, M. A., Beurskens, F. J., Engelberts, P. J., Parren, P. W. H. I., van de Winkel, J. G. J., & Taylor, R. P. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101189 · Cited by 140 · cited 1×
“Thus, in vivo, exhaustion of effector mechanisms, including complement and effector cells such as NK and macrophages, as well as loss of target antigen by trogocytosis or internalization, can limit the efficacy of anti-tumor mAbs [18,134,139,152,155,156].”
BackgroundSelf-citationTetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals
Lapalombella, R., Yeh, Y.-Y., Wang, L., Ramanunni, A., Rafiq, S., Jha, S., Staubli, J., Lucas, D. M., Mani, R., Herman, S. E. M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.040 · Cited by 140
Complement in monoclonal antibody therapy of cancer
Rogers, L. M., Veeramani, S., & Weiner, G. J. (2014) · Immunologic Research · doi:10.1007/s12026-014-8542-z · Cited by 138 · cited 1×
“The importance of complement activation by unconjugated IgG1 mAbs in contributing to the anti-tumor response in vivo has been the subject of a considerable series of investigations, even for rituximab, which has been the most studied therapeutic mAb [2,4,98].”
BackgroundCampbell, K. S., Cohen, A. D., & Pazina, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02551 · Cited by 136
Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms
Cleary, K. L. S., Chan, H. T. C., James, S., Glennie, M. J., & Cragg, M. S. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601473 · Cited by 134 · cited 2×
“Thus, even though distance of the epitopes from the membrane, as well as antibody affinity, may affect CDC as well as ADCC/ADCP [55], recent data suggest that major role intermolecular interactions and the capacity of the mAbs to form hexamers are major determinants for CDC. Similarly, among a panel of anti-CD38 antib…”
BackgroundRegulation of regulators: Role of the complement factor H-related proteins
Cserhalmi, M., Papp, A., Brandus, B., Uzonyi, B., & Józsi, M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101341 · Cited by 131 · cited 1×
“, thereby protecting them from complement attack [94].”
BackgroundGolay, J., Cittera, E., Gaetano, N. D., Manganini, M., Mosca, M., Nebuloni, M., van Rooijen, N., Vago, L., & Introna, M. (2006) · PubMed · Cited by 129
Self-citationComplement in therapy and disease
Melis, J. P. M., Strumane, K., Ruuls, S. R., Beurskens, F. J., Schuurman, J., & Parren, P. W. H. I. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.028 · Cited by 125
Valgardsdottir, R., Cattaneo, I., Klein, C., Introna, M., Figliuzzi, M., & Golay, J. (2017) · Blood · doi:10.1182/blood-2016-08-735605 · Cited by 124
Self-citationMamidi, S., Cinci, M., Hasmann, M., Fehring, V., & Kirschfink, M. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.011 · Cited by 122
Antibody‐mediated complement activation in pathology and protection
Goldberg, B. S., & Ackerman, M. E. (2020) · Immunology & Cell Biology · doi:10.1111/imcb.12324 · Cited by 120 · cited 1×
“, a weak but constant hydrolytic activation of C3), but the alternative pathway can amplify complement activation (via nascent C3b) first generated by the classical pathway (Figure 1) [26,27].”
BackgroundBeurskens, F. J., Lindorfer, M. A., Farooqui, M., Beum, P. V., Engelberts, P., Mackus, W. J. M., Parren, P. W. H. I., Wiestner, A., & Taylor, R. P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103693 · Cited by 119 · cited 2×
“Rapid complement activation with deposition of C3b and iC3b on the CLL cell membrane has been demonstrated very soon after rituximab and ofatumumab infusion [138,139].”
BackgroundSelf-citationBrown, E. J., Joiner, K. A., Cole, R. M., & Berger, M. (1983) · Infection and Immunity · doi:10.1128/iai.39.1.403-409.1983 · Cited by 113
Nijhof, I. S., van Bueren, J. J. L., van Kessel, B., Andre, P., Morel, Y., Lokhorst, H. M., van de Donk, N. W. C. J., Parren, P. W. H. I., & Mutis, T. (2015) · Haematologica · doi:10.3324/haematol.2014.117531 · Cited by 112 · cited 11×
“Interestingly, in MM patients who progressed after daratumumab treatment, their malignant plasma cells had elevated levels of CD55 and CD59, but not of CD46, suggesting that resistance to daratumumab in vivo may be related at least in part to resistance to CDC [80].”
BackgroundInfluentialNovel insights into the expression pattern of anaphylatoxin receptors in mice and men
Laumonnier, Y., Karsten, C. M., & Köhl, J. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.05.019 · Cited by 108 · cited 1×
“They can induce chemotaxis of the cells to the tumors and the generation of a profound pro-inflammatory state [26,34].”
BackgroundTaylor, R. P., & Lindorfer, M. A. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.003 · Cited by 101 · cited 5×
“The importance of complement activation by unconjugated IgG1 mAbs in contributing to the anti-tumor response in vivo has been the subject of a considerable series of investigations, even for rituximab, which has been the most studied therapeutic mAb [2,4,98].”
BackgroundSelf-citationBeum, P. V., Lindorfer, M. A., & Taylor, R. P. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2916 · Cited by 100
Self-citationBologna, L., Gotti, E., Da Roit, F., Intermesoli, T., Rambaldi, A., Introna, M., & Golay, J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202645 · Cited by 99 · cited 4×
“Nonetheless, ofatumumab-mediated CDC is still antigen density dependent [62,64].”
BackgroundSelf-citationComplement alone drives efficacy of a chimeric antigonococcal monoclonal antibody
Gulati, S., Beurskens, F. J. M., de Kreuk, B.-J., Roza, M., Zheng, B., DeOliveira, R. B., Shaughnessy, J., Nowak, N., Taylor, R. P., Botto, M., et al. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000323 · Cited by 97 · cited 1×
“Fc mutations that favor hexamerization of antibodies targeting EGFR, CD38, or CD37 can render them strong effectors through CDC [24,25,44,45,57,58] and are being developed for clinical use [59,60].”
BackgroundSelf-citationBeum, P. V., Mack, D. A., Pawluczkowycz, A. W., Lindorfer, M. A., & Taylor, R. P. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.8120 · Cited by 94
Self-citationTakei, K., Yamazaki, T., Sawada, U., Ishizuka, H., & Aizawa, S. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.09.008 · Cited by 94 · cited 1×
“Increased CD55/CD59 expression was observed on cell lines selected in vitro for resistance to rituximab and complement [82].”
BackgroundEffect of alemtuzumab on neoplastic B cells.
Golay, J., Manganini, M., Rambaldi, A., & Introna, M. (2004) · PubMed · Cited by 93
Self-citationHuman CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
Hu, W., Ge, X., You, T., Xu, T., Zhang, J., Wu, G., Peng, Z., Chorev, M., Aktas, B. H., Halperin, J. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3016 · Cited by 91
Wang, Y., Zhang, H., & He, Y.-W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01574 · Cited by 90 · cited 1×
“Complement factors also modulate T cell responses directly through CR1, CR2 (complement receptor 2, CD21), C1q, C3aR, and C5aRs receptors [42,43].”
BackgroundMacor, P., Secco, E., Mezzaroba, N., Zorzet, S., Durigutto, P., Gaiotto, T., Maso, L. D., Biffi, S., Garrovo, C., Capolla, S., et al. (2014) · Leukemia · doi:10.1038/leu.2014.185 · Cited by 84 · cited 2×
“It is clear that manipulation of the complement cascade, through the design of anti-tumor mAbs with increased ability to activate complement [44,59,96], or with mAbs that hyperactivate the complement cascade [97] or block soluble or membrane bound inhibitors [63,84,91], may all be feasible strategies to enhance the CD…”
BackgroundHsu, Y.-F., Ajona, D., Corrales, L., Lopez-Picazo, J. M., Gurpide, A., Montuenga, L. M., & Pio, R. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-139 · Cited by 84 · cited 2×
“Indeed rituximab [63,65], ofatumumab [48,62,70], alemtuzumab [22], daratumumab [21], trastuzumab [77], and cetuximab [99] have all been reported to activate complement in vitro, albeit with highly variable efficacity.”
BackgroundComplement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL
Middleton, O., Cosimo, E., Dobbin, E., McCaig, A. M., Clarke, C., Brant, A., Leach, M., Michie, A. M., & Wheadon, H. (2014) · Leukemia · doi:10.1038/leu.2014.146 · Cited by 82
Non-identical twins: Different faces of CR3 and CR4 in myeloid and lymphoid cells of mice and men
Erdei, A., Lukácsi, S., Mácsik-Valent, B., Nagy-Baló, Z., Kurucz, I., & Bajtay, Z. (2019) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2017.11.025 · Cited by 82 · cited 1×
“Furthermore the expression of complement receptors on different immune cell types including DCs is not identical between mice and men, making the study of the relevance of a possible vaccine effect via these molecules even more difficult [130].”
Background‘‘Homologous restriction’’ in complement lysis: roles of membrane complement regulators
Morgan, B. P., van den Berg, C. W., & Harris, C. L. (2005) · Xenotransplantation · doi:10.1111/j.1399-3089.2005.00237.x · Cited by 81
Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity
Zent, C. S., & Elliott, M. R. (2017) · The FEBS Journal · doi:10.1111/febs.13961 · Cited by 80 · cited 1×
“Thus, in vivo, exhaustion of effector mechanisms, including complement and effector cells such as NK and macrophages, as well as loss of target antigen by trogocytosis or internalization, can limit the efficacy of anti-tumor mAbs [18,134,139,152,155,156].”
BackgroundCellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies
VanDerMeid, K. R., Elliott, M. R., Baran, A. M., Barr, P. M., Chu, C. C., & Zent, C. S. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0319 · Cited by 78
Wang, Y., Yang, Y.-J., Wang, Z., Liao, J., Liu, M., Zhong, X., Zheng, H. Y., & Wang, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6555 · Cited by 76
Daratumumab for the Treatment of Multiple Myeloma
Plesner, T., & Krejcik, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01228 · Cited by 75
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden
Boross, P., Jansen, J. H. M., de Haij, S., Beurskens, F. J., van der Poel, C. E., Bevaart, L., Nederend, M., Golay, J., van de Winkel, J. G. J., Parren, P. W. H. I., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.047159 · Cited by 74
Self-citationBarth, M. J., Hernandez‐Ilizaliturri, F. J., Mavis, C. K., Tsai, P., Gibbs, J. F., Deeb, G., & Czuczman, M. S. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08966.x · Cited by 73 · cited 1×
“Indeed rituximab [63,65], ofatumumab [48,62,70], alemtuzumab [22], daratumumab [21], trastuzumab [77], and cetuximab [99] have all been reported to activate complement in vitro, albeit with highly variable efficacity.”
BackgroundOostindie, S. C., van der Horst, H. J., Kil, L. P., Strumane, K., Overdijk, M. B., van den Brink, E. N., van den Brakel, J. H. N., Rademaker, H. J., van Kessel, B., van den Noort, J. A., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0292-7 · Cited by 73
Self-citationChen (2009) · Oncology Reports · doi:10.3892/or_00000368 · Cited by 69
Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
Franssen, L. E., Stege, C. A. M., Zweegman, S., van de Donk, N. W. C. J., & Nijhof, I. S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041195 · Cited by 69 · cited 2×
“Thus the multiple effects of anti-CD38 antibodies, including daratumumab, probably all contribute to their efficacy in vivo and CDC may be dispensable in some cases [100].”
BackgroundGrandjean, C. L., Montalvão, F., Celli, S., Michonneau, D., Bréart, B., Garcia, Z., Perro, M., Freytag, O., Gerdes, C. A., & Bousso, P. (2016) · Scientific Reports · doi:10.1038/srep34382 · Cited by 67
Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium
Zent, C. S., Chen, J. B., Kurten, R. C., Kaushal, G. P., Lacy, H. M., & Schichman, S. A. (2003) · Leukemia Research · doi:10.1016/j.leukres.2003.09.011 · Cited by 66 · cited 1×
“Indeed rituximab [63,65], ofatumumab [48,62,70], alemtuzumab [22], daratumumab [21], trastuzumab [77], and cetuximab [99] have all been reported to activate complement in vitro, albeit with highly variable efficacity.”
BackgroundTerui, Y., Sakurai, T., Mishima, Y. M., Mishima, Y., Sugimura, N., Sasaoka, C., Kojima, K., Yokoyama, M., Mizunuma, N., Takahashi, S., et al. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2006.00139.x · Cited by 65
Kern, D. J., James, B. R., Blackwell, S. E., Gassner, C., Klein, C., & Weiner, G. J. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.781169 · Cited by 64 · cited 2×
“In a series of provocative papers, Weiner et al. reported that NK-cell-mediated killing (ADCC) of rituximab-opsonized B cells is substantially reduced if complement is activated; their results suggest that the deposited C3 fragments sterically hinder interaction of NK cell FcγRIII (CD16) with the Fc region of cell-bou…”
BackgroundCook, E. M., Lindorfer, M. A., van der Horst, H. J., Oostindie, S. C., Beurskens, F. J. M., Schuurman, J., Zent, C. S., Burack, R., Parren, P. W. H. I., & Taylor, R. P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600648 · Cited by 64 · cited 1×
“Fc mutations that favor hexamerization of antibodies targeting EGFR, CD38, or CD37 can render them strong effectors through CDC [24,25,44,45,57,58] and are being developed for clinical use [59,60].”
BackgroundSelf-citationBellone, S., Roque, D. M., Cocco, E., Gasparrini, S., Bortolomai, I., Buza, N., Abu-Khalaf, M. M., Silasi, D.-A., Ratner, E., Azodi, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.132 · Cited by 62
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
Oostindie, S. C., van der Horst, H. J., Lindorfer, M. A., Cook, E. M., Tupitza, J. C., Zent, C. S., Burack, R., VanDerMeid, K. R., Strumane, K., Chamuleau, M. E. D., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.207266 · Cited by 60 · cited 1×
“the negative interference that is sometimes observed between these effects or through the use of mAb combinations that may be specifically favorable for these mechanisms [175].”
BackgroundSelf-citationBaig, N. A., Taylor, R. P., Lindorfer, M. A., Church, A. K., LaPlant, B. R., Pettinger, A. M., Shanafelt, T. D., Nowakowski, G. S., & Zent, C. S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302954 · Cited by 59 · cited 2×
“This means that an antibody with a greater CDC or ADCC potential in vitro may in any case be limited in vivo by these mechanisms [2,141,172].”
BackgroundSelf-citationTerminal complexes of the complement system: New structural insights and their relevance to function
Morgan, B. P., Walters, D., Serna, M., & Bubeck, D. (2016) · Immunological Reviews · doi:10.1111/imr.12461 · Cited by 58 · cited 1×
“On this basis, it should be clear that C9 polymerization generally correlates with effective cell lysis [30,32,33].”
BackgroundDeligne, C., Metidji, A., Fridman, W. H., & Teillaud, J. (2014) · Leukemia · doi:10.1038/leu.2014.275 · Cited by 58 · cited 7×
“Furthermore the expression of complement receptors on different immune cell types including DCs is not identical between mice and men, making the study of the relevance of a possible vaccine effect via these molecules even more difficult [130].”
BackgroundInfluentialSchütze, K., Petry, K., Hambach, J., Schuster, N., Fumey, W., Schriewer, L., Röckendorf, J. L., Menzel, S., Albrecht, B., Haag, F., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02553 · Cited by 56 · cited 1×
“Fc mutations that favor hexamerization of antibodies targeting EGFR, CD38, or CD37 can render them strong effectors through CDC [24,25,44,45,57,58] and are being developed for clinical use [59,60].”
BackgroundUtilization of complement receptors in immune cell–microbe interaction
Lukácsi, S., Mácsik‐Valent, B., Nagy‐Baló, Z., Kovacs, K. G., Kliment, K., Bajtay, Z., & Erdei, A. (2020) · FEBS Letters · doi:10.1002/1873-3468.13743 · Cited by 54 · cited 2×
“In other words, NK cells and macrophages recognize tumor-cell-associated complement fragments—in particular C3b, iC3b, and C3d and mediate cytotoxicity or phagocytosis [36].”
BackgroundA Humanized Mouse Identifies the Bone Marrow as a Niche with Low Therapeutic IgG Activity
Lux, A., Seeling, M., Baerenwaldt, A., Lehmann, B., Schwab, I., Repp, R., Meidenbauer, N., Mackensen, A., Hartmann, A., Heidkamp, G. F., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.041 · Cited by 53
Cittera, E., Leidi, M., Buracchi, C., Pasqualini, F., Sozzani, S., Vecchi, A., Waterfield, J. D., Introna, M., & Golay, J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6616 · Cited by 51 · cited 1×
“rituximab [122] and in the syngeneic EL4-CD20 model [123].”
BackgroundSelf-citationAnti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells
Capuano, C., Romanelli, M., Pighi, C., Cimino, G., Rago, A., Molfetta, R., Paolini, R., Santoni, A., & Galandrini, R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0781 · Cited by 51
Xu, W., Miao, K., Zhu, D., Cheng, F., Zhu, H., Dong, H., Wang, D., Wu, Y., Qiao, C., & Li, J. (2011) · International Journal of Cancer · doi:10.1002/ijc.25560 · Cited by 50
Baig, N. A., Taylor, R. P., Lindorfer, M. A., Church, A. K., LaPlant, B. R., Pavey, E. S., Nowakowski, G. S., & Zent, C. S. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.681657 · Cited by 48 · cited 1×
“However, the sensitivity of the cells to alemtuzumab-mediated CDC remained quite high, indicating that the CD52 epitope on the cells recognized by alemtuzumab was clearly still expressed at high levels, and that complement control proteins on the cells were not upregulated to provide protection against the alemtuzumab…”
BackgroundSelf-citationVerma, M. K., Clemens, J. L., Burzenski, L. M., Sampson, S. B., Brehm, M. A., Greiner, D. L., & Shultz, L. D. (2017) · Journal of Immunological Methods · doi:10.1016/j.jim.2017.03.021 · Cited by 48 · cited 1×
“Similarly, an immunodeficient NOD scid gamma (NSG) mouse model with active complement suggests a contribution of both complement and immune cells for tumor control by rituximab [121].”
BackgroundBoross, P., Jansen, J. H. M., Pastuła, A., van der Poel, C. E., & Leusen, J. H. W. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.01.004 · Cited by 47
Fries, L. F., Siwik, S. A., Malbrán, A., & Frank, M. M. (1987) · PubMed Central · Cited by 46
Hörl, S., Bánki, Z., Huber, G. C., Ejaz, A., Windisch, D., Müllauer, B., Willenbacher, E., Steurer, M., & Stoiber, H. (2013) · Leukemia · doi:10.1038/leu.2013.169 · Cited by 46 · cited 1×
“FH has been shown to diminish the efficacy of ofatumumab-mediated CDC of CLL cells in vitro [89,90].”
BackgroundNatsume, A., Shimizu‐Yokoyama, Y., Satoh, M., Shitara, K., & Niwa, R. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01327.x · Cited by 45 · cited 1×
“For this reason, some groups have attempted to measure the role of complement and immune cells in human whole blood assays, which may at least better reflect what takes place in the circulation immediately after mAb infusion in patients [50,64,137].”
BackgroundComplement System: a Neglected Pathway in Immunotherapy
Bordron, A., Bagacean, C., Tempescul, A., Berthou, C., Bettacchioli, É., Hillion, S., & Renaudineau, Y. (2019) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08741-0 · Cited by 45
Mamidi, S., Höne, S., Teufel, C., Sellner, L., Zenz, T., & Kirschfink, M. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.979688 · Cited by 44 · cited 1×
“In contrast to CD55/CD59, there is little evidence, using antibodies, that blocking CD46 alone has any effect on IgG1 triggered CDC [86].”
ResultGe, X., Wu, L., Hu, W., Fernandes, S. M., Wang, C., Li, X., Brown, J. R., & Qin, X. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0647 · Cited by 44
You, T., Hu, W., Ge, X., Shen, J., & Qin, X. (2011) · Cellular and Molecular Immunology · doi:10.1038/cmi.2010.35 · Cited by 43
LIU, M., Yang, Y., Zheng, H. Y., Zhong, X., Wang, Y., Wang, Z., Wang, Y.-G., & Wang, Y. (2014) · Oncology Reports · doi:10.3892/or.2014.3496 · Cited by 42 · cited 1×
“A correlation between CD55 and CD59 expression and response of breast cancer patients to trastuzumab has been suggested [164].”
BackgroundBetting, D. J., Yamada, R. E., Kafi, K., SAID, J. W., van Rooijen, N., & Timmerman, J. M. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ab23f1 · Cited by 42 · cited 1×
“rituximab [122] and in the syngeneic EL4-CD20 model [123].”
BackgroundCharbonneau, B., Maurer, M. J., Fredericksen, Z. S., Zent, C. S., Link, B. K., Novak, A. J., Ansell, S. M., Weiner, G. J., Wang, A. H., Witzig, T. E., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23273 · Cited by 41
Klepfish, A., Schattner, A., Ghoti, H., & Rachmilewitz, E. A. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70106-7 · Cited by 36
Barth, M. J., Mavis, C. K., Czuczman, M. S., & Hernandez‐Ilizaliturri, F. J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0056 · Cited by 36
Beum, P. V., Lindorfer, M. A., Peek, E. M., Stukenberg, P. T., de Weers, M., Beurskens, F. J., Parren, P. W. H. I., van de Winkel, J. G. J., & Taylor, R. P. (2011) · European Journal of Immunology · doi:10.1002/eji.201041204 · Cited by 35 · cited 1×
“Similarly, among a panel of anti-CD38 antibodies, only daratumumab was found to be a potent complement activator, although the epitope recognized by daratumumab overlaps with that of other antibodies that are poor activators, suggesting that, in this case, the specific orientation of daratumumab may allow for more eff…”
BackgroundSelf-citationCosta, D., Venè, R., Benelli, R., Romairone, E., Scabini, S., Catellani, S., Rebesco, B., Mastracci, L., Grillo, F., Minghelli, S., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01150 · Cited by 34
van Meerten, T., Rozemuller, H., Hol, S., Moerer, P., Zwart, M. C., Hagenbeek, A., Mackus, W. J. M., Parren, P. W. H. I., van de Winkel, J. G. J., Ebeling, S. B., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.025783 · Cited by 32
Dzietczenia, J., Wróbel, T., Mazur, G. J., Poręba, R., Jaźwiec, B., & Kuliczkowski, K. (2009) · Medical Oncology · doi:10.1007/s12032-009-9278-9 · Cited by 31 · cited 1×
“Although some correlations have been found in cases of lymphoma patients treated with rituximab and chemotherapy [160,161], this has not been confirmed in other studies [162], even with rituximab used as monotherapy [163].”
ResultLindorfer, M. A., Cook, E. M., Tupitza, J. C., Zent, C. S., Burack, R., de Jong, R. N., Beurskens, F. J. M., Schuurman, J., Parren, P. W. H. I., & Taylor, R. P. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.12.007 · Cited by 31
Self-citationTammen, A., Derer, S., Schwanbeck, R., Rösner, T., Kretschmer, A., Beurskens, F. J. M., Schuurman, J., Parren, P. W. H. I., & Valerius, T. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601268 · Cited by 31 · cited 2×
“It is clear that manipulation of the complement cascade, through the design of anti-tumor mAbs with increased ability to activate complement [44,59,96], or with mAbs that hyperactivate the complement cascade [97] or block soluble or membrane bound inhibitors [63,84,91], may all be feasible strategies to enhance the CD…”
BackgroundBordron, A., Bagacean, C., Mohr, A., Tempescul, A., Bendaoud, B., Deshayes, S., Dalbiès, F., Buors, C., Saad, H., Berthou, C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25657 · Cited by 31 · cited 2×
“Some investigators have also observed a correlation between CDC in vitro and response of CLL patients to rituximab in vivo, in support of a role of complement in vivo in humans, either directly or indirectly, by enhancing cell-mediated mechanisms [93].”
BackgroundHörl, S., Bánki, Z., Huber, G., Ejaz, A., Müllauer, B., Willenbacher, E., Steurer, M., & Stoiber, H. (2013) · Haematologica · doi:10.3324/haematol.2013.089615 · Cited by 29 · cited 1×
“FH has been shown to diminish the efficacy of ofatumumab-mediated CDC of CLL cells in vitro [89,90].”
BackgroundRogers, L. M., Mott, S. L., Smith, B. J., Link, B. K., Sahin, D. G., & Weiner, G. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1275 · Cited by 27
Gordan, S., Albert, H., Danzer, H., Lux, A., Biburger, M., & Nimmerjahn, F. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.111 · Cited by 26
Song, G., Song, G., Ni, H., Gu, L., Liu, H. S., Chen, B., He, B., Pan, Y., Wang, S., & Cho, W. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140818211103 · Cited by 24 · cited 1×
“Although some correlations have been found in cases of lymphoma patients treated with rituximab and chemotherapy [160,161], this has not been confirmed in other studies [162], even with rituximab used as monotherapy [163].”
ResultBeyer, I., Cao, H., Persson, J., Wang, H., Liu, Y., Yumul, R., Li, Z., Woodle, D., Manger, R. L., Gough, M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.212 · Cited by 23 · cited 1×
“However, the lack of effect of anti-CD46 mAbs may be due to incomplete functional block of the protein, since an adenovirus-derived recombinant ligand of CD46, called Ad35K++, which induces cross-linking and internalization of the molecule, also significantly increased rituximab efficacy in vitro and in vivo in mouse…”
BackgroundThree major uncertainties in the antibody therapy of cancer
Stevenson, G. T. (2014) · Haematologica · doi:10.3324/haematol.2013.084640 · Cited by 22 · cited 1×
“Rather, most murine models suggest that FcγRs and myeloid cells are required and suggest a strong role of ADCP in the mechanism of action of many unconjugated mAbs, including rituximab, ofatumumab, obinutuzumab, cetuximab, trastuzumab, and daratumumab [11,103,108–113], as reviewed by Stevenson [114].”
BackgroundPlesner, T., van de Donk, N. W. C. J., & Richardson, P. G. G. (2020) · Cells · doi:10.3390/cells9020378 · Cited by 22
Song, G., Cho, W. C. S., Gu, L., He, B., Pan, Y., & Wang, S. (2014) · Medical Oncology · doi:10.1007/s12032-014-0056-y · Cited by 21 · cited 1×
“Although some correlations have been found in cases of lymphoma patients treated with rituximab and chemotherapy [160,161], this has not been confirmed in other studies [162], even with rituximab used as monotherapy [163].”
ResultDifferential effects of anaphylatoxin C5a on antigen presenting cells, roles for C5aR1 and C5aR2
Zaal, A., van Ham, S. M., & ten Brinke, A. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.014 · Cited by 21
Derer, S., Cossham, M., Rösner, T., Kellner, C., Beurskens, F. J. M., Schwanbeck, R., Lohse, S., Sina, C., Peipp, M., & Valerius, T. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501458 · Cited by 20 · cited 1×
“Similar cross-talk has been shown for other antibodies such as cetuximab [9] and a complement optimized anti-EGFR mAb was found to induce enhanced ADCC by PMNs [124].”
BackgroundMusolino, A., Boggiani, D., Pellegrino, B., Zanoni, D., Sikokis, A., Missale, G., Silini, E. M., Maglietta, G., Frassoldati, A., & Michiara, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102927 · Cited by 20
Tempescul, A., Bagacean, C., Riou, C., Bendaoud, B., Hillion, S., Debant, M., Buors, C., Berthou, C., & Renaudineau, Y. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12573 · Cited by 19
Winkler, M. T., Bushey, R. T., Gottlin, E. B., Campa, M. J., Guadalupe, E., Volkheimer, A. D., Weinberg, J. B., & Patz, E. F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179841 · Cited by 19 · cited 2×
“It is clear that manipulation of the complement cascade, through the design of anti-tumor mAbs with increased ability to activate complement [44,59,96], or with mAbs that hyperactivate the complement cascade [97] or block soluble or membrane bound inhibitors [63,84,91], may all be feasible strategies to enhance the CD…”
BackgroundLoeff, F. C., van Egmond, H. M. E., Nijmeijer, B. A., Falkenburg, J. H. F., Halkes, C. J. M., & Jedema, I. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1281411 · Cited by 17
Fresh frozen plasma as a complement source
Taylor, R. P. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70114-6 · Cited by 16
Self-citationTaylor, R. P., Lindorfer, M. A., Cook, E. M., Beurskens, F. J. M., Schuurman, J., Parren, P. W. H. I., Zent, C. S., VanDerMeid, K. R., Burack, R., Mizuno, M., et al. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.05.016 · Cited by 16
Self-citationGolay, J. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.06.002 · Cited by 16 · cited 3×
“Rituximab efficiently activates CDC, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP) in vitro, and these different mechanisms must all contribute to its efficacy [4,7].”
BackgroundSelf-citationProtein engineering to target complement evasion in cancer
Carter, D., & Lieber, A. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.11.007 · Cited by 15 · cited 1×
“These data indeed provide considerable evidence that CD46, like CD55 and CD59, modulates the efficacy of at least some IgG1 therapeutic antibodies [88].”
BackgroundFelberg, A., Urban, A., Borowska, A., Stasiłojć, G., Taszner, M., Hellmann, A. R., Blom, A. M., & Okrój, M. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02304-0 · Cited by 14 · cited 1×
“It is clear that manipulation of the complement cascade, through the design of anti-tumor mAbs with increased ability to activate complement [44,59,96], or with mAbs that hyperactivate the complement cascade [97] or block soluble or membrane bound inhibitors [63,84,91], may all be feasible strategies to enhance the CD…”
BackgroundLindorfer, M. A., Beum, P. V., & Taylor, R. P. (2013) · Antibodies · doi:10.3390/antib2040598 · Cited by 13 · cited 1×
“reported that blocking its action increases CDC of CLL cells mediated by rituximab or ofatumumab [95].”
BackgroundSelf-citationOffner, F. C., Robak, T., Janssens, A. M., Babu, G., Kloczko, J. S., Grosicki, S., Mayer, J., Panagiotidis, P., Schuh, A., Pettitt, A. R., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16625 · Cited by 12 · cited 1×
“Therefore, one can conclude that the three anti-CD20 antibodies used for B-NHL and CLL treatment along with chemotherapy do not show greatly different efficacies in vivo, at least not such differences as were hoped for when they were selected and developed on the basis of their higher efficacy or different mechanisms…”
BackgroundGuo, B., Ma, Z.-W., Li, H., Xu, G., Zheng, P., Zhu, B., Wu, Y., & Zou, Q. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.03.507 · Cited by 11 · cited 1×
“Targeting the third short consensus repeat (SCR3) of CD55 with antibodies or small molecules appears to be required for CDC enhancement [73].”
BackgroundŠebejová, L., Borský, M., Jašková, Z., Potěšil, D., Navrkalová, V., Malčíková, J., Šrámek, M., Doubek, M., Loja, T., Pospíšilová, Š., et al. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.06.003 · Cited by 10
The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia
Evers, M., Jak, M., & Leusen, J. H. W. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1508444 · Cited by 8
Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
Tuscano, J. M., Poh, C., Rosenberg, A. S., Jonas, B. A., Abedi, M., Barisone, G. A., Schwab, E., Lundeberg, K., & Kaesberg, P. R. (2020) · Journal of Hematology · doi:10.14740/jh721 · Cited by 2
Research works printed but not linked: 2
- 5. Lindorfer, M.A.; Koehl, J.; Taylor, R.P. Interactions between the complement system and Fcgamma receptors. In IgG Fc: Linking Adaptive and Innate Immunity ; Nimmerhahn, F., Ackerman, M.E., Eds.; Elsevier Press: Amsterdam, The Netherlands, 2013; pp. 49-74.
- 165. Lindorfer, M.A.; Bakker, P.W.H.I.; Parren, P.W.; Taylor, R.P. Ofatumumab: A next-generation human therapeutic CD20 antibody with potent complement-dependent cytotoxicity. In Handbook of Therapeutic Antibodies ; Duebel, S., Reichert, J.M., Eds.; Wiley-VCH: Weinberg, Germany, 2013; pp. 1733-1744.
Cited by
A guide to complement biology, pathology and therapeutic opportunity
Mastellos, D. C., Hajishengallis, G., & Lambris, J. D. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00926-1 · Cited by 320
“For decades, complement activation was merely considered an auxiliary mechanism that potentiates the cytolytic action of tumour-specific antibodies through the process of complement-dependent cytotoxicity 14,135 .”
Cancer therapy with antibodies
Paul, S., Konig, M. F., Pardoll, D. M., Bettegowda, C., Papadopoulos, N., Wright, K. M., Gabelli, S. B., Ho, M., van Elsas, A., & Zhou, S. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00690-x · Cited by 248
“Thus, the IgG4 format probably protects PD1-expressing effector T cells from being inadvertently killed via ADCC or CDC.”
InfluentialMechanisms of Therapeutic Antitumor Monoclonal Antibodies
Tsao, L.-C., Force, J., & Hartman, Z. C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1109 · Cited by 198
“Moreover, this can result in the assembly of the membrane attack complex (MAC), which allows for direct cellular target destruction (12).”
BackgroundAdvances in antibody-based therapy in oncology
Zinn, S., Vazquez-Lombardi, R., Zimmermann, C., Sapra, P., Jermutus, L., & Christ, D. (2023) · Nature Cancer · doi:10.1038/s43018-023-00516-z · Cited by 184
Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies
Golay, J., Andrea, A. E., & Cattaneo, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.929895 · Cited by 141
Self-citation
Metadata
- Authors
- Golay, J., & Taylor, R. P.
- Affiliations
- Ospedale Papa Giovanni XXIII (IT)
- University of Virginia (US)
- Corresponding author
- Golay, Josée
- Taylor, Ronald P.
- Venue
- Antibodies
- Publisher
- MDPI AG
- Published
- 2020-10-28
- Volume
- 9
- Issue
- 4
- Pages
- 58
- ISSN
- 2073-4468 (ISSN-L)
- PMC
- PMC7709112
- OpenAlex
- W3097855394
- Cited by
- 104
- References
- 177
- Citations by year
- 2026: 11 · 2025: 20 · 2024: 28 · 2023: 18 · 2022: 13 · 2021: 13 · 2020: 1
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Antibodies (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (IG19036, 5x1000 ISM)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- complement activation, IgG1, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, complement-dependent cytotoxicity, classical complement pathway, CD55, CD59, complement receptors, C3a, C5a, natural killer cells, macrophages
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.